Vical Inc. and partner Astellas Pharma Inc. remain hopeful for positive data from an ongoing phase III study testing cytomegalovirus (CMV) vaccine ASP0113 in hematopoietic stem cell transplant (HCT) recipients, set to read out late next year, despite the product's phase II miss in solid organ transplant patients.